Innovative medicines based on the biology of orexin
Restoring wakefulness and addressing orexin deficiency in neurological disordersOur Focus
Our unique platform
We aspire to explore the full therapeutic potential of orexin agonists for the treatment of rare diseases and common disorders.
Our diverse approaches to activating orexin receptors and drug delivery systems aim to maximize the number of patients who will benefit from orexin agonists.
The Science Behind Orexin
Orexins, also called ‘hypocretins’, are neurotransmitters acting in the brain that regulate wakefulness, arousal, and energy homeostasis. We are developing orexin receptor agonists and positive modulators to treat disorders with dysfunction of orexin signaling.
Narcolepsy Type 1 (NT1) is a rare disease caused by the profound loss of orexin-producing neurons. Orexin agonists will directly address the underlying disease pathology of NT1 to restore orexin neurotransmission in the brain, and also have potential in a broad range of other indications.
We are combining an unprecedented suite of novel technologies to enable the successful discovery and development of orexin agonists and positive modulators. At the heart of Orexia Therapeutics is a collaboration with Sosei Heptares which leverages unique GPCR structural biology capabilities.